|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Synageva BioPharma (GEVA) Announces Pricing of Public Offering of Common Stock
1/4/2013 9:37:41 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 2,150,000 shares at $47.53 per share. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 322,500 additional shares of common stock. Morgan Stanley and J.P. Morgan are acting as joint book-running managers in the offering, and Cowen and Company, Canaccord Genuity Inc., and Leerink Swann LLC are acting as co-managers in the offering.
|
|
|
|
|
|
|
|
|
|
|